Earth Science Tech (ETST) 10-Q 14 Nov 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	000-55000
Entity Registrant Name	EARTH SCIENCE TECH, INC.
Entity Central Index Key	0001538495
Entity Tax Identification Number	80-0931484
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	8950 SW 74th CT
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33156
City Area Code	(786)
Local Phone Number	375-7281
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	ETST
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		221,695,496

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Current Assets:
Cash	$ 1,205	$ 26,942
Accounts Receivable(net allowance of $0 and $101,404 respectively )
Prepaid expenses and other current assets
Inventory
Total current assets	1,205	26,942
Other Assets:
Due from RxCompound	303,057	25,000
Prepaid Acquisition Costs	51,500	25,000
Total other assets	354,557	50,000
Total Assets	355,762	76,942
Current Liabilities:
Accounts payable	175,524	202,270
PPP Loan		31,750
Issa Loan Advance	50,000	50,000
Issa Revolving Note	250,000	50,000
SBA EDIL Loan	102,956	106,800
Accrued expenses	181,873	311,610
Accrued settlement	510,886	584,886
Promissory Note-GHS		30,000
SBA  Payable	8,796
Due to RX Compound	110,363	1,895
Note Payable-Mario Portella	27,500	27,500
Notes payable - related party	59,558	59,558
Total current liabilities	2,383,335	1,882,355
Commitments and contingencies
Stockholders’ (Deficit) Equity:
Common stock, par value $0.001 per share, 750,000,000 shares authorized; 59,051,966 and 53,851,966 shares issued and outstanding as of September 30, 2022 and March 31, 2022 respectively	59,053	53,853
Preferred stock B par value $0.001 per share 1,000,000 authorized and outstanding as of September 30, 2022	1,000
Additional paid-in capital	28,264,452	28,264,452
Accumulated deficit	(30,352,078)	(30,123,718)
Total stockholders’ (Deficit)Equity	(2,027,573)	(1,805,413)
Total Liabilities and Stockholders’ (Deficit) Equity	355,762	76,942
Convertible Notes Strongbow Advisors [Member]
Current Liabilities:
Convertible Notes  -GHS	220,000
Convertible Notes Vcmaji Irrevocable Trust [Member]
Current Liabilities:
Convertible Notes  -GHS	150,000
Convertible Note 2-VCMAJI Irrevocable Trust	200,000
Convertible Note G H S [Member]
Current Liabilities:
Interest Payable-Portella Note		83,475
Promissory Note G H S [Member]
Current Liabilities:
Interest Payable-Portella Note		14,429
Convertible Notes G H S [Member]
Current Liabilities:
Convertible Notes  -GHS		326,838
Portella Note [Member]
Current Liabilities:
Interest Payable-Portella Note	1,447	344
Fox Rothchild [Member]
Current Liabilities:
Accrued Settlement-Steven Warm	218,462
Ghs [Member]
Current Liabilities:
Accrued Settlement-Steven Warm	80,000
Steven Warm [Member]
Current Liabilities:
Accrued Settlement-Steven Warm	$ 20,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 0	$ 101,404
Common Stock, Par or Stated Value Per Share		$ 0.001
Common Stock, Shares Authorized		750,000,000
Common Stock, Shares, Outstanding	59,051,966	53,851,966
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Preferred Stock, Shares Outstanding	1,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Revenue		$ 2,455		$ 9,945
Cost of revenues		1,332		5,077
Gross Profit		1,123		4,868
Operating Expenses:
Compensation - officers	45,269	9,500	76,519	15,212
Officer compensation stock	4,500		4,500
General and administrative	12,944	30,313	155,941	37,509
Professional fees	4,000		9,200	900
Loss on disposal of assets				1,712
Litigation Expense			512,725
Cost of legal proceedings	10,200	7,500	10,200	7,267
Total operating expenses	76,913	47,313	769,085	62,600
Loss from operations	(76,913)	(46,190)	(769,085)	(57,732)
Other Income (Expenses)	10,417	3,408,636	558,025	3,408,930
Other Income
Interest expense	(5,646)	(4,397)	(11,244)	(5,588)
Int Exp-SBA Loan	(981)	(1,000)	(4,952)	(1,000)
Total other income (expenses)	3,235	3,387,589	540,725	3,376,721
Net Profit/(Loss) before income taxes	(73,678)	3,341,399	(228,360)	3,318,989
Income taxes
Net Profit/(Loss)	(73,678)	3,341,399	(228,360)	3,318,989
Convertible Notes G H S [Member]
Operating Expenses:
Portela Interest		(14,289)		(25,621)
Promissory Note G H S [Member]
Operating Expenses:
Portela Interest		(1,361)		(2,707)
Convertible Notes Portela [Member]
Operating Expenses:
Portela Interest	$ (555)		$ (1,104)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 52,853		$ 28,245,452	$ (33,319,388)	$ (5,021,083)
Beginning balance, shares at Jun. 30, 2021	52,851,966
Common stock issued for cash
Common stock issued for cash, shares
Common stock issued for services
Common stock issued for services, shares
Common stock issued for officer compensation
Common stock issued for officer compensation, shares
Common stock issued for Conversion on Note
Common stock issued for Conversion on Note, shares
Net Profit/(Loss)				3,341,399	3,341,399
Ending balance, value at Sep. 30, 2021	$ 52,853		28,245,452	(29,977,989)	(1,679,684)
Ending balance, shares at Sep. 30, 2021	52,851,966
Common stock issued for cash	$ 500		9,500		10,000
Common stock issued for cash, shares	500,000
Common stock issued for services
Common stock issued for services, shares
Common stock issued for officer compensation
Common stock issued for officer compensation, shares
Net Profit/(Loss)				(115,048)	(115,048)
Common stock issued for officer compensation, shares
Ending balance, value at Dec. 31, 2021	$ 53,353		28,254,952	(30,093,037)	(1,784,732)
Ending balance, shares at Dec. 31, 2021	53,351,966
Common stock issued for cash	$ 500		9,500		10,000
Common stock issued for cash, shares	500,000
Common stock issued for services
Common stock issued for services, shares
Common stock issued for officer compensation
Common stock issued for officer compensation, shares
Common stock issued for Conversion on Note
Common stock issued for Conversion on Note, shares
Net Profit/(Loss)				(30,681)	(30,681)
Ending balance, value at Mar. 31, 2022	$ 53,853		28,264,452	(30,123,718)	(1,805,413)
Ending balance, shares at Mar. 31, 2022	53,851,966
Common stock issued for cash
Common stock issued for cash, shares
Common stock issued for services
Common stock issued for services, shares
Common stock issued for officer compensation
Common stock issued for officer compensation, shares
Common stock issued for Conversion on Note
Common stock issued for Conversion on Note, shares
Net Profit/(Loss)				(154,682)	(154,682)
Ending balance, value at Jun. 30, 2022	$ 53,853		28,264,452	(30,278,400)	(1,960,095)
Ending balance, shares at Jun. 30, 2022	53,851,966
Beginning balance, value at Mar. 31, 2022	$ 53,853		28,264,452	(30,123,718)	(1,805,413)
Beginning balance, shares at Mar. 31, 2022	53,851,966
Net Profit/(Loss)					(228,360)
Ending balance, value at Sep. 30, 2022	$ 59,053	$ 1,000	28,264,452	(30,352,078)	(2,027,573)
Ending balance, shares at Sep. 30, 2022	59,051,966	1,000,000
Beginning balance, value at Jun. 30, 2022	$ 53,853		28,264,452	(30,278,400)	(1,960,095)
Beginning balance, shares at Jun. 30, 2022	53,851,966
Common stock issued for cash
Common stock issued for cash, shares
Common stock issued for services	$ 1,700				1,700
Common stock issued for services, shares	1,700,000
Common stock issued for officer compensation	$ 3,500				3,500
Common stock issued for officer compensation, shares	3,500,000
Common stock issued for Conversion on Note
Common stock issued for Conversion on Note, shares
Net Profit/(Loss)				(73,678)	(73,678)
Preferred stock B issued for officer compensation		$ 1,000
Preferred stock B issued for officer compensation, Shares		1,000,000
Ending balance, value at Sep. 30, 2022	$ 59,053	$ 1,000	$ 28,264,452	$ (30,352,078)	$ (2,027,573)
Ending balance, shares at Sep. 30, 2022	59,051,966	1,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flow From Operating Activities:
Net Profit/(Loss)	$ (228,360)	$ 3,318,989
Changes in operating assets and liabilities:
Increase/Decrease in prepaid expenses and other current assets	(424,838)	13,305
Increase in accrued settlement	273,462	(3,408,637)
Decrease/Increase in inventory		5,077
Decrease in accounts payable	3,999	50,435
Net Cash Used in Operating Activities	(375,737)	(20,831)
Investing Activities:
Purchases of property and equipment		1,712
Net Cash Used in Investing Activities		1,712
Financing Activities:
Proceeds from issuance of common stock		28,175
Proceeds from notes payable- related party
Proceeds from Convertible Notes	350,000
Intrinsic value of Conv Notes-Addtl Paid-in-Capital
Net Cash Provided by Financing Activities	350,000	28,175
Net Decrease in Cash	(25,737)	9,056
Cash - Beginning of period	26,942	16,161
Cash - End of period	$ 1,205	$ 25,217

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 — Organization and Nature of Operations Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010 subsequently changed to the State of Florida on June 27, 2022. As of November 3, 2021, the Company entered into an agreement that is currently pending to acquire RxCompoundStore.com, LLC (“RxCompound”) and Peaks Curative, LLC. (“Peaks”) through the purchase of 100% of the outstanding equity securities both entities. Under the terms of the transaction, the Seller agreed to exchange one Hundred (100) RxCompound Units and One Hundred (100) Peaks Units in exchange for 3,000,000 shares of the Company’s common stock together with $ 300,000 300,000 0.50 1.00 RxCompound is a compounding pharmacy that has historically focused on men’s health, specifically medical products directed at ED such as Tadalfil, and Sildenafil Citrate (the generic names for Cialis and Viagra, respectively) and longevity. RxCompound is in process on obtaining a sterile compounding room expected to launch January 2023 to provide sterile products for injection. Peaks is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is in its final stages on upgrading its website after its soft launch to and increase product offering. Peaks full launch is anticipated for January 2023. Earth Science Foundation (“ESF”) is a favored entity of ETST, effectively being a non-profit organization on February 11, 2019, and is structured to accept grants and donations to those in need.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of presentation The Company’s accounting policies used in the presentation of the accompanying consolidated financial statements conform to accounting principles generally accepted in the United States of America (“US GAAP”) and have been consistently applied. Principles of consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary Earth Science Foundation, Inc. is a non-profit favored entity of the Company. After the conditions to closing have been met, RxCompoundand and Peaks will also be wholly owned subsidiaries of the Company. All intercompany balances and transactions have been eliminated on consolidation. Use of estimates and assumptions The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and assumptions include the fair value of financial instruments; the accrual of the legal settlement, the carrying value recoverability and impairment, if any, of long-lived assets, including the estimated useful lives of fixed assets; the valuation allowance of deferred tax assets; stock-based compensation, the valuation of the inventory reserves and the assumption that the Company will continue as a going concern. Those significant accounting estimates or assumptions bear the risk of change since there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Carrying value, recoverability, and impairment of long-lived assets Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC’) 360 to evaluate its long-lived assets. The Company’s long-lived assets, which include property and equipment and a patent are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events. Impairment of changes, if any, are included in operating expenses. On June 4, 2019, the Company discontinued its patents based upon the advice of IP counsel. IP counsel indicated that only one patent application had a reasonable chance of being granted and based upon this advice the Company determined that it would discontinue this approach of using the patent process to protect product formulations in general and rather, revert to proprietary formulae and trade secrets to protect its intellectual property (unless it was clear from the beginning of the process that the formula was patentable. As a result, on June 4, 2019, the company wrote down or otherwise impaired approximately $ 27,000 in legal fees that had previously been attributed to its Patents and took a corresponding write-off to “impairment expense.” Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less to be cash and cash equivalents. Related parties The Company follows ASC 850 for the identification of related parties and disclosure of related party transactions. Pursuant to this ASC related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. Commitments and contingencies The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. Revenue recognition The Company follows and implements ASC 606, Revenue from Contracts with Customers for revenue recognition. Although the new revenue standard is expected to have an immaterial effect, if any, on the Company’s ongoing net income, management did implement changes to the Company’s processes related to revenue recognition and the control activities within them. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures. The Company recognizes revenue from product sales or services rendered when control of the promised goods are transferred to the company’s clients in an amount that reflects the consideration to which management expect to be entitled in exchange for those goods and services. To achieve this core principle, management apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation. Inventories The Company during did not hold any inventories during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will have inventories stated at the lower of cost or market using the first in, first out (FIFO) method from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward. A reserve will be established if necessary to reduce excess or obsolete inventories to their net realizable value. Cost of Sales There were no components of costs of due to the Company not having any revenues during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will include product costs and shipping costs to customers and any inventory adjustments from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward. Shipping and Handling Costs There were no shipping and handling fees billed due to the Company not having any revenues during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will include shipping and handling fees billed to customers as revenues and shipping and handling costs for shipments to customers as cost of revenues once from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward. Research and development Research and development costs are expensed as incurred. The Company’s research and development expenses relate to its engineering activities, which consist of the design and development of new products for specific customers, as well as the design and engineering of new or redesigned products for the industry in general. Income taxes The Company follows ASC 740 in accounting for income taxes. Deferred tax assets and liabilities are determined based on the estimated future tax effects of net operating loss carry forwards and temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records a valuation allowance for its deferred tax assets when management concludes that it is not more likely than not those assets will be recognized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2021, the Company has no t recorded any unrecognized tax benefits. Interest and penalties related to liabilities for uncertain tax positions will be charged to interest and operating expenses, respectively. The Company has net operating loss carry forwards (NOL) for income tax purposes of approximately $ 6,150,613 . This loss is allowed to be offset against future income until the year 2039 when the NOL’s will expire . The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through September 30, 2022. There was no change in the valuation allowance for the periods ended September 30, 2022, and 2021. Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. The Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes are limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income subsequent to the ownership change. Net loss per common share The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculations are determined by dividing net results from operations by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As of September 30, 2022, the Company has no warrants that are anti-dilutive and not included in the calculation of diluted loss per share. Cash flows reporting The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant this standard. Stock based compensation The Company follows ASC 718 in accounting for its stock-based compensation to employees. These standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price of the Company’s common stock as of the date in which the obligation for payment of service is incurred. Company accounts for transactions in which service are received from non-employees in exchange for equity instruments based on the fair value of the equity instrument exchanged in accordance with ASC 505-50. Property and equipment Property and equipment are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method based upon the estimated useful lives of the respective assets as follows: Schedule of Property Plant and Equipment Leasehold improvements Shorter of useful life or term of lease Signage 5 years Furniture and equipment 5 years Computer equipment 5 years The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from accounts and any resulting gains or losses are included in operations. Recently issued accounting pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. This guidance will supersede Topic 605, Revenue Recognition, in addition to other industry-specific guidance, once effective. The new standard requires a company to recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, as a revision to ASU 2014-09, which revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e., the original adoption date per ASU 2014-09). In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies certain aspects of the principal- versus-agent guidance, including how an entity should identify the unit of accounting for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions. The amendments also reframe the indicators to focus on evidence that an entity is acting as a principal rather than as an agent. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property, which will determine whether it recognizes revenue over time or at a point in time. The amendments also clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow entities to disregard items that are immaterial in the context of a contract. The Company continues to assess the impact this new standard may have on its ongoing financial reporting. The Company has identified its revenue streams both by contract and product type and is assessing each for potential impacts. For the revenue streams assessed, the Company does not anticipate a material impact in the timing or amount of revenue recognized. In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. Instead, if “the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.” The guidance is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will have on its Consolidated Financial Statements. All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable. Intangible Assets The Company’s balance of intangible assets on the condensed consolidated balance sheet net of accumulated amortizations $ 0 and $ 0 as of September 30, 2022, and September 30, 2021, Reclassification Certain amounts from the prior period have been reclassified to conform to the current period presentation.

Going Concern

Going Concern	6 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 — Going Concern The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. On September 30, 2022, the Company had negative working capital, an accumulated deficit of $ 30,352,078 . These factors raise substantial doubt about the Company’s ability to continue as a going concern. Subsequently to the period ending September 30, 2022, the Company and the sellers amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company is now a holding entity set to acquire companies in the health and wellness space currently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompound and Peaks. The Company’s cash position may not be sufficient to pay its obligations and support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate sufficient revenues may provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate sufficient revenues by acquiring companies and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenues. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Related Party Balances and Tran

Related Party Balances and Transactions	6 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Balances and Transactions	Note 4 - Related Party Balances and Transactions The Seller and current owner of RxCompound and Peaks Curative is Mario Tabraue, the brother of the Company’s CEO, Nickolas S. Tabraue. Although strictly speaking, the acquisition was negotiated in an arms-length transaction and both the Company and Mario Tabraue had separate counsel, each of whom contributed to the acquisition agreement. The Company’s Board of Directors, the Company’s Management and the Successor Receiver all concluded that the purchase price, consisting of 3 million shares of ETST common stock and $ 300,000 , was a fair and reasonable purchase price and that, given the various liabilities that ETST may exit receivership owing and the various legacy issues and the associated risks, the value the two acquisition targets represent is in all likelihood substantially greater than the purchase price would otherwise suggest, although there is not an accurate method to determine its value to a company that is in the position that this Company finds itself. Subsequently to the period ending September 30, 2022, the Company and the sellers amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events).

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 5 – Stockholders’ Equity During the three months ended September 30, 2022, and 2021, the Company issued 0 and 0 common shares for an aggregate sales price of $ 0 and $ 0 respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 — Commitments and Contingencies Legal Proceedings On January 11, 2019, the Company received notice that Strongbow Advisors, Inc. and Robert Stevens (“Stevens”, and together with Strongbow, the “Receiver”) was appointed by the Nevada District Court, as Receiver for the Registrant in Case No. A-18-784952-C (the “Order). The Company sought the appointment of the Receiver after it found itself in an imminent danger of insolvency following the issuance by an arbitration panel of an award (the “Award”) in the sum of $ 3,994,522 in favor of Cromogen Biotechnology Corporation (“Cromogen”) in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc. (the “Cromogen Litigation”). The Nevada District Court found that the Company was in fact insolvent and ordered the appointment of the Receiver. The Award consisted of a sum for breach of contract against the Company in the amount of $ 120,265 , a sum for costs and fees against the Company in the amount of $ 111,057 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $ 3,763,200 . The District Court in Florida had confirmed the Award granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen. As part of the impact of the receivership, the Court issued a Writ of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is in receivership. As a result of the “Blanket Stay” the Company’s estate was protected from creditors and interference with its administration was prevented while the Company’s financial issues are being fully analyzed and resolved. As part of this process, creditors will be notified and required to provide claims in writing under oath on or before the deadline stated in the notice provided by the Receiver or those claims will be barred under NRS §78.675. The Blanket Stay will remain in place unless otherwise waived by the Receiver, or it was vacated by the Court or alternatively, lifted by the Court, upon a “motion to lift stay” duly made and approved by the Nevada District Court. On November 7, 2019, the Receiver for Earth Science Tech, Inc., a Nevada corporation (the “Company”) filed a motion for preliminary injunction against Majorca Group Ltd. in the 8th Judicial District in Clark County, Nevada. The filing requests a show cause hearing whereby the Company will request the Court grants it motion to cancel certain shares and class of stock and to nullify certain amendments of the Articles of Incorporation. Specifically, the Company is asking that Majorca Group Ltd. be restricted from selling, transferring, converting, encumbering, hypothecating, obtaining loans against or in any fashion or in any way transferring their shares of common and preferred stock in the Company. Additionally, the motion seeks a Freezing Injunction over any broker, bank, any financial institution, attorney, or agent holding shares of the Company as well as any proceeds from shares of the Company. On January 27, 2020, Earth Science Tech, Inc., a Nevada corporation (the “Company”) reached a confidential settlement with Majorca Group, Ltd (“Majorca”). The Receiver will withdraw its motion for injunction over the Majorca common and preferred shares. The Settlement Agreement provided that Majorca Group, Ltd. and all relevant parties will, within 10 days of execution of the settlement agreement, return 18,000,000 common shares and 5,200,000 Series A Preferred Stock held by Majorca for cancellation. The Series A Preferred Stock class was initially going to be returned to treasury and then reissued to Nickolas S. Tabraue. However, the prior receiver never reissued the shares and claimed to have cancelled the shares completely as a class. However, that was not done either, the 5,200,000 shares were canceled by agreement with Majorca and as the articles of incorporation and / or a certificate of designation for the Series A Preferred Stock was not amended or canceled by amendment or in any other manner canceled, changed or eliminated as a class with such change recorded with the Nevada Secretary of State, it was therefore not canceled and instead simply returned to the treasury. The remaining 6,520,000 common shares held by Majorca is subject to lockup agreement and sales may only be made pursuant to a limited strict bleed-out agreement administered by a third party as part of what is commonly referred to in the financial services industry as a “10b-5 Plan ”. On January 19, 2021, one of the Company’s largest shareholders served and filed a notice of motion and motion to intervene against Robert L. Stevens and Strongbow Advisors, Inc. (individually or collectively referred to as “Receiver”) this action was later joined by additional shareholders representing approximately 33% of the issued and outstanding shares of the Company at that time. This motion to intervene, at its heart, was based upon and resulted from, what the interveners saw as, a lack of transparency by the Receiver . What was filed was initially based upon concerns of Mr. Stevens’ lack of transparency. However, as the matter progressed in court, additional concerns risen and on August 27, 2021, Stevens and Strongbow were discharged and removed and William Leonard was appointed to replace them as Receiver, by the Nevada District Court. Mr. Leonard was reviewing various matters, including past invoices presented by Stevens, as well as his conduct during the time he acted as Receiver for the Company as well as others that the prior Receiver had a prior relationship with that have derived benefits from working with the prior Receiver. The outcome of this review is uncertain at the time and a wide number of outcomes is possible. The Company was optimistic that it will be able to emerge from receivership under the new receiver, in a reorganized position that will allow it to proceed with the acquisitions of the three entities. Combined, these entities present a larger opportunity to realize the synergies that they have among themselves and in so doing, the Company believed it will be possible for shareholder value to increase at a faster rate than would otherwise be possible with only its CBD business and licensing of its medical device, Hygee, The Company has executed a joint letter of intent with three entities involved in the durable medical equipment, retail sales and compounding pharmacy businesses with the objective of negotiating the final terms of a transaction that will result in the Company’s acquisition of these entities. Following the discharge and removal of Robert L. Stevens and Strongbow Advisors, Inc., the successor Receiver, William A Leonard, Jr., of Crisis Management, Inc., undertook the investigation of the former receiver’s actions, practices, and claims for fees for work he alleges was performed. The Successor Receiver then issued his report evaluating Mr. Stevens fees claims and found that there were no outstanding fees due. The court had set an evidentiary hearing that was scheduled and rescheduled for the court to consider the successor receivers conclusions as well as the former receiver’s potential liabilities to the Company. The evidentiary hearing was later canceled due to the Company settling with Stevens and his company Strongbow Advisors, Inc., Dubowsky law, and Fox Rothchild LLP. In the settlement the Company has agreed to pay Fox Rothchild’s fees and expenses in an amount equal to $ 270,000 15,000 the agreement with the remaining $255,000 being paid over 17 months as follows: $10,000 per month commencing May 1, 2022 then $16,538 per month commencing September 1, 2022 and continuing on the same day each succeeding month through November 1, 2022; then $16,849.85 per month (which includes 7.5% per annum interest component) commencing December 1, 2022 and continuing on the same day of each succeeding month through April 1, 2023; then $17,037.91 per month (which includes 12% per annum interest component) commencing May 1, 2023 provided however, if on or before October 1, 2022 Fox Rothchild irrevocably receives payments from behalf of the Company under the agreement totaling $230,000 (inclusive of the timely payment of $15,000 made 3 days after entry of settlement), then the Fox Rothschild fees shall be deemed satisfied in full 220,000.00 April 24, 2023 10 20 On August 30, 2021, the Company reached a settlement with Cromogen for $ 585,885.90 in a month-to-month payment plan starting January 1, 2022, having the initial payment of $ 45,000 and $ 10,000 each month followed with the final payment set on December 1, 2026. If the Company was able to and decides to pay the settlement entirely prior to January 1, 2022 commencement, a $ 85,885.90 reduction would have taken place bringing the total settlement to $ 500,000 . If the Company defaulted on Cromogen’s settlement, a confession of judgement would be executed for the amount of $ 970,000 , representing the total amount of Cromogen’s unsecured claims, less any amount paid by the Company, plus costs and attorney fees incurred to obtain and enforce the judgement. As of the month of March Cromogen’s settlement terms were being renegotiated due to the Company extended review time taken by the Successor Receiver as well as continuing negotiations with Stevens. The Company renegotiated payment terms on April 27, 2022 amended settlement with Cromogen for $ 585,885 in a month-to-month payment plan that started June 1, 2022, having the initial payment of $ 45,000 then $ 10,000 each month followed with the final payment set on July 1, 2027. If the Company defaults on Cromogen’s settlement, a confession of judgement will be executed for $ 970,000 , representing the total amount of Cromogen’s unsecured claims, less any amount paid by the Company, plus costs and attorney fees incurred to obtain the enforce of judgement. Subsequently to the period ending September 30, 2022, Cromogen’s balance has been satisfied, (See Note 8, Subsequent Events). On May 31, 2022, Earth Science Tech, Inc., a Nevada corporation (the “Company”), exited receivership under the direction of William A. Leonard Jr. of Crisis Management, Inc. (“Receiver”). The Company’s board of directors has resumed full control of the Company pursuant to NRS 78.645(1). The exit was granted by the Eighth Judicial Court in Clark County Nevada. Through the receivership process and Receiver, the Company has positioned itself for future success by (i) entering into settlement agreements with claimed creditors; and (ii) negotiating the pending acquisition of two operating entities. The total receivership administrative fees and costs were $ 137,850.93 and paid in full within the month of August 2022. Lease Agreements On August 31, 2021, the Company entered into an agreement with JCR Medical Equipment, Inc., a Florida Corporation to lease a 1,000 square foot facility consisting of office and warehouse space that is a part of its 13,000 /sq. ft. facility located at 10650 NW 29th Terrace Doral, FL 33172. JCR Medical Equipment, Inc. is part of the Company’s two-part acquisition plan described in the Company’s current report filed with the Commission on Form 8-K on September 10, 2021. The Company on or about November 3, 2021, entered into an agreement to acquire both RxCompound and Peaks. Subsequently to the period ending September 30, 2022, the Company is presently located at RxCompound’s location at 8950 SW 74 th

Balance Sheet and Income Statem

Balance Sheet and Income Statement Footnotes	6 Months Ended
	Sep. 30, 2022
Balance Sheet And Income Statement Footnotes
Balance Sheet and Income Statement Footnotes	Note 7 — Balance Sheet and Income Statement Footnotes A c As of September 30, 2022, ROU Asset was $ 0 , and Lease Liability-Current was $ 0 . Accounts payable are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities Accrued expenses of $ 181,873 as of September 30, 2022 mainly represent, $ 126,410 in accrued payroll for the company’s CEO and CFO, and the remainder for of accrued interest on Notes Payable. General and administrative expenses were $ 12,944 and $ 30,313 for September 30, 2022, and 2021 respectively. For the six months ended September 30, 2022, $ 2,297 in payroll taxes, $ 2,489 in employee compensation and the remainder were on miscellaneous expenses. . Professional fees were $ 4,000 for the three months ended September 30, 2022. Other income was $ 10,200 for the three months ended September 30, 2022. Interest expense was $( 5,646 ) and $( 4,397 ) for three months ended September 30, 2022 and 2021. Interest expense for three months ended September 30, 2022 was mainly due to Convertible Notes Mario Portela ,Issa El-Chelkh, and VCMAJI Irrevocable Trust.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 8 — Subsequent Events During October 2022, Mr. Giorgio R. Saumat (“Saumat”) purchased $ 625,624 .40 of the Company’s debt (“Acquired Debt”) from various of the Company’s existing debt holders. Upon completion of the purchase, Saumat demanded repayment of the Acquired Debt by the Company. On October 24, 2022, the Company and Saumat entered into a settlement agreement whereby the Company agreed to issue 62,562,440 shares of its restricted Common Stock and 1,000,000 shares of its Series B Preferred Stock to Saumat in full satisfaction and the complete cancellation of any and all amounts due and owing under the Acquired Debt. On October 25, 2022, the Company and Dr. Issa El-Cheikh entered into a Settlement and Release Agreement whereby the Company agreed to issue 16,300,000 shares of its restricted Common Stock to Dr. Issa El-Cheikh in full satisfaction and complete cancellation of $ 155,791 .21 due and owing to Dr. Issa El-Cheikh through various note instruments. On October 25, 2022, the Company and Mario Portela entered into a Settlement and Release Agreement whereby the Company agreed to issue 2,750,000 shares of its restricted Common Stock to Mr. Portala in full satisfaction and complete cancellation of the $ 27,500 convertible promissory note held by Mr. Portela. On or around October 24, 2022, and by virtue of the transactions contemplated in Item 1.01 above, Nickolas S. Tabraue and Mario G. Tabraue collectively cancelled 1,000,000 shares of Company Series B Preferred stock and the Company reissued said shares to Saumat as partial consideration under the Settlement Agreement whereby the Acquired Debt was cancelled. Based on the rights and preferences set forth in the Series B Certificate of Designation, the share assignment results in Saumat having a controlling vote with respect to all matters requiring a shareholder vote. On October 25, 2022, Nickolas S. Tabraue, the Company’s CEO and Director and Mario G. Tabraue, the Company’s President and Director have both agreed to defer receiving salary compensation until the Company is cashflow positive for 3 consecutive bi-week payroll periods. Once the Company has achieved cashflow positive status, the Company will renegotiate employment agreements with Nickolas S. Tabraue and Mario G. Tabraue. On November 8, 2022, the Company, and the sellers of both RxCompound and Peaks (collectively, the “Target”) amended the Purchase Agreement for the Membership Units of the Targets, dated November 3, 2021 (“Agreement”). Pursuant to the terms of the Amendment

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Company’s accounting policies used in the presentation of the accompanying consolidated financial statements conform to accounting principles generally accepted in the United States of America (“US GAAP”) and have been consistently applied.
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary Earth Science Foundation, Inc. is a non-profit favored entity of the Company. After the conditions to closing have been met, RxCompoundand and Peaks will also be wholly owned subsidiaries of the Company. All intercompany balances and transactions have been eliminated on consolidation.
Use of estimates and assumptions	Use of estimates and assumptions The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and assumptions include the fair value of financial instruments; the accrual of the legal settlement, the carrying value recoverability and impairment, if any, of long-lived assets, including the estimated useful lives of fixed assets; the valuation allowance of deferred tax assets; stock-based compensation, the valuation of the inventory reserves and the assumption that the Company will continue as a going concern. Those significant accounting estimates or assumptions bear the risk of change since there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.
Carrying value, recoverability, and impairment of long-lived assets	Carrying value, recoverability, and impairment of long-lived assets Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC’) 360 to evaluate its long-lived assets. The Company’s long-lived assets, which include property and equipment and a patent are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events. Impairment of changes, if any, are included in operating expenses. On June 4, 2019, the Company discontinued its patents based upon the advice of IP counsel. IP counsel indicated that only one patent application had a reasonable chance of being granted and based upon this advice the Company determined that it would discontinue this approach of using the patent process to protect product formulations in general and rather, revert to proprietary formulae and trade secrets to protect its intellectual property (unless it was clear from the beginning of the process that the formula was patentable. As a result, on June 4, 2019, the company wrote down or otherwise impaired approximately $ 27,000 in legal fees that had previously been attributed to its Patents and took a corresponding write-off to “impairment expense.”
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less to be cash and cash equivalents.
Related parties	Related parties The Company follows ASC 850 for the identification of related parties and disclosure of related party transactions. Pursuant to this ASC related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
Commitments and contingencies	Commitments and contingencies The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Revenue recognition	Revenue recognition The Company follows and implements ASC 606, Revenue from Contracts with Customers for revenue recognition. Although the new revenue standard is expected to have an immaterial effect, if any, on the Company’s ongoing net income, management did implement changes to the Company’s processes related to revenue recognition and the control activities within them. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures. The Company recognizes revenue from product sales or services rendered when control of the promised goods are transferred to the company’s clients in an amount that reflects the consideration to which management expect to be entitled in exchange for those goods and services. To achieve this core principle, management apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.
Inventories	Inventories The Company during did not hold any inventories during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will have inventories stated at the lower of cost or market using the first in, first out (FIFO) method from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward. A reserve will be established if necessary to reduce excess or obsolete inventories to their net realizable value.
Cost of Sales	Cost of Sales There were no components of costs of due to the Company not having any revenues during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will include product costs and shipping costs to customers and any inventory adjustments from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward.
Shipping and Handling Costs	Shipping and Handling Costs There were no shipping and handling fees billed due to the Company not having any revenues during the period end September 30, 2022. Subsequently to the period ending September 30, 2022, the Company amended the Purchase Agreement consummating the merger, (see Note 8, Subsequent Events). The Company will include shipping and handling fees billed to customers as revenues and shipping and handling costs for shipments to customers as cost of revenues once from its subsequently merged wholly owned subsidiaries RxCompound and Peaks moving forward.
Research and development	Research and development Research and development costs are expensed as incurred. The Company’s research and development expenses relate to its engineering activities, which consist of the design and development of new products for specific customers, as well as the design and engineering of new or redesigned products for the industry in general.
Income taxes	Income taxes The Company follows ASC 740 in accounting for income taxes. Deferred tax assets and liabilities are determined based on the estimated future tax effects of net operating loss carry forwards and temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records a valuation allowance for its deferred tax assets when management concludes that it is not more likely than not those assets will be recognized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2021, the Company has no t recorded any unrecognized tax benefits. Interest and penalties related to liabilities for uncertain tax positions will be charged to interest and operating expenses, respectively. The Company has net operating loss carry forwards (NOL) for income tax purposes of approximately $ 6,150,613 . This loss is allowed to be offset against future income until the year 2039 when the NOL’s will expire . The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through September 30, 2022. There was no change in the valuation allowance for the periods ended September 30, 2022, and 2021. Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. The Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes are limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income subsequent to the ownership change.
Net loss per common share	Net loss per common share The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculations are determined by dividing net results from operations by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As of September 30, 2022, the Company has no warrants that are anti-dilutive and not included in the calculation of diluted loss per share.
Cash flows reporting	Cash flows reporting The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant this standard.
Stock based compensation	Stock based compensation The Company follows ASC 718 in accounting for its stock-based compensation to employees. These standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price of the Company’s common stock as of the date in which the obligation for payment of service is incurred. Company accounts for transactions in which service are received from non-employees in exchange for equity instruments based on the fair value of the equity instrument exchanged in accordance with ASC 505-50.
Property and equipment	Property and equipment Property and equipment are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method based upon the estimated useful lives of the respective assets as follows: Schedule of Property Plant and Equipment Leasehold improvements Shorter of useful life or term of lease Signage 5 years Furniture and equipment 5 years Computer equipment 5 years The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from accounts and any resulting gains or losses are included in operations.
Recently issued accounting pronouncements	Recently issued accounting pronouncements In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. This guidance will supersede Topic 605, Revenue Recognition, in addition to other industry-specific guidance, once effective. The new standard requires a company to recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, as a revision to ASU 2014-09, which revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e., the original adoption date per ASU 2014-09). In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies certain aspects of the principal- versus-agent guidance, including how an entity should identify the unit of accounting for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions. The amendments also reframe the indicators to focus on evidence that an entity is acting as a principal rather than as an agent. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property, which will determine whether it recognizes revenue over time or at a point in time. The amendments also clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow entities to disregard items that are immaterial in the context of a contract. The Company continues to assess the impact this new standard may have on its ongoing financial reporting. The Company has identified its revenue streams both by contract and product type and is assessing each for potential impacts. For the revenue streams assessed, the Company does not anticipate a material impact in the timing or amount of revenue recognized. In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. Instead, if “the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.” The guidance is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will have on its Consolidated Financial Statements. All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.
Intangible Assets	Intangible Assets The Company’s balance of intangible assets on the condensed consolidated balance sheet net of accumulated amortizations $ 0 and $ 0 as of September 30, 2022, and September 30, 2021,
Reclassification	Reclassification Certain amounts from the prior period have been reclassified to conform to the current period presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Property Plant and Equipment	Schedule of Property Plant and Equipment Leasehold improvements Shorter of useful life or term of lease Signage 5 years Furniture and equipment 5 years Computer equipment 5 years

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative) - USD ($)		3 Months Ended					6 Months Ended
	Nov. 03, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022
Stock Issued During Period, Value, New Issues				$ 10,000	$ 10,000
Rx Compound Store LLC and Peaks Curative LLC [Member]
Business Combination, Contingent Consideration Arrangements, Description							Under the terms of the transaction, the Seller agreed to exchange one Hundred (100) RxCompound Units and One Hundred (100) Peaks Units in exchange for 3,000,000 shares of the Company’s common stock together with $300,000 in cash. The transaction is structured in a way that allows the Buyer to raise the $300,000 cash component of the purchase price over time as it seeks and received additional funding. The cash component is managed separately, and under the terms of the Agreement, $0.50 of every $1.00 raised by the Company shall be held in escrow until the full $300,000 can be paid in full (unless the Seller waives and postpones the right to immediate payment as the Company is raising capital) at which time the parties will officially close the acquisition. The Company has until 12/31/2022 to raise the funds required to close the transaction.
Stock Issued During Period, Shares, New Issues	300,000
Stock Issued During Period, Value, New Issues	$ 300,000
Share Price	$ 0.50
Rx Compound Store LLC and Peaks Curative LLC [Member] | Buyer [Member]
Share Price	$ 1
Rx Compound Store LLC and Peaks Curative LLC [Member]
Equity Method Investment, Ownership Percentage	100%

Schedule of Property Plant and

Schedule of Property Plant and Equipment (Details)	6 Months Ended
	Sep. 30, 2022
Signage [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		6 Months Ended
	Jun. 04, 2019	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Legal Fees	$ 27,000
Income Tax Examination, Likelihood of Unfavorable Settlement		greater than 50%
Unrecognized Tax Benefits				$ 0
Operating Loss Carryforwards		$ 6,150,613
Net operating loss carry forwards expiration date		the year 2039 when the NOL’s will expire
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			$ 0
Finite-Lived Intangible Assets, Accumulated Amortization		$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 30,352,078	$ 30,123,718

Related Party Balances and Tr_2

Related Party Balances and Transactions (Details Narrative) - Rx Compound Store LLC and Peaks Curative LLC [Member] shares in Millions	6 Months Ended
	Sep. 30, 2022 USD ($) shares
Restructuring Cost and Reserve [Line Items]
Stock Issued During Period, Shares, Acquisitions | shares	3
Stock Issued During Period, Value, Acquisitions | $	$ 300,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - Common Stock [Member] - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	0	0
Sale of Stock, Consideration Received Per Transaction	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)

3 Months Ended

6 Months Ended

May 31, 2022 USD ($)

Apr. 27, 2022 USD ($)

Aug. 30, 2021 USD ($)

Jan. 19, 2021 USD ($)

Jan. 27, 2020

Jan. 11, 2019 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Jun. 02, 2022 USD ($)

Jan. 02, 2022 USD ($)

Aug. 31, 2021 ft²

Litigation settlement expense

$ 512,725

Area of Land | ft²

1,000

William A. Leonard Jr. [Member]

Administrative Fees Expense

$ 137,850.93

Settlement Agreement [Member]

Litigation settlement expense

$ 270,000

Litigation settlement amount awarded from other party

$ 15,000

Loss contingency settlement agreemnt terms, descripition

the agreement with the remaining $255,000 being paid over 17 months as follows: $10,000 per month commencing May 1, 2022 then $16,538 per month commencing September 1, 2022 and continuing on the same day each succeeding month through November 1, 2022; then $16,849.85 per month (which includes 7.5% per annum interest component) commencing December 1, 2022 and continuing on the same day of each succeeding month through April 1, 2023; then $17,037.91 per month (which includes 12% per annum interest component) commencing May 1, 2023 provided however, if on or before October 1, 2022 Fox Rothchild irrevocably receives payments from behalf of the Company under the agreement totaling $230,000 (inclusive of the timely payment of $15,000 made 3 days after entry of settlement), then the Fox Rothschild fees shall be deemed satisfied in full

Litigation settlement amount

$ 220,000

Settlement agreement date

April 24, 2023

Litigation settlement percentage

10%

Debt interest rate

20%

Strongbow Advisors, Inc. [Member]

[custom:DescriptionOfConfidentialSettlement]

On January 19, 2021, one of the Company’s largest shareholders served and filed a notice of motion and motion to intervene against Robert L. Stevens and Strongbow Advisors, Inc. (individually or collectively referred to as “Receiver”) this action was later joined by additional shareholders representing approximately 33% of the issued and outstanding shares of the Company at that time. This motion to intervene, at its heart, was based upon and resulted from, what the interveners saw as, a lack of transparency by the Receiver

Cromongen Biotechnology Corporation [Member]

Loss Contingency, Damages Sought, Value

$ 3,994,522

Increase in accrued settlement

120,265

[custom:CostsAndFeesAmount]

111,057

[custom:ConversionValue]

$ 3,763,200

Litigation settlement expense

$ 585,885

$ 585,885.90

[custom:LitigationSettlementInitialPayments-0]

$ 10,000

$ 10,000

$ 45,000

$ 45,000

[custom:ContingencyExpectedTrialCommencement]

85,885.90

Gain (Loss) Related to Litigation Settlement

500,000

Litigation Settlement, Amount Awarded to Other Party

$ 970,000

Majorca Group, Ltd [Member]

[custom:DescriptionOfConfidentialSettlement]

On January 27, 2020, Earth Science Tech, Inc., a Nevada corporation (the “Company”) reached a confidential settlement with Majorca Group, Ltd (“Majorca”). The Receiver will withdraw its motion for injunction over the Majorca common and preferred shares. The Settlement Agreement provided that Majorca Group, Ltd. and all relevant parties will, within 10 days of execution of the settlement agreement, return 18,000,000 common shares and 5,200,000 Series A Preferred Stock held by Majorca for cancellation. The Series A Preferred Stock class was initially going to be returned to treasury and then reissued to Nickolas S. Tabraue. However, the prior receiver never reissued the shares and claimed to have cancelled the shares completely as a class. However, that was not done either, the 5,200,000 shares were canceled by agreement with Majorca and as the articles of incorporation and / or a certificate of designation for the Series A Preferred Stock was not amended or canceled by amendment or in any other manner canceled, changed or eliminated as a class with such change recorded with the Nevada Secretary of State, it was therefore not canceled and instead simply returned to the treasury. The remaining 6,520,000 common shares held by Majorca is subject to lockup agreement and sales may only be made pursuant to a limited strict bleed-out agreement administered by a third party as part of what is commonly referred to in the financial services industry as a “10b-5 Plan

JCR Medical Equipment Inc [Member]

Area of Land | ft²

13,000

Balance Sheet and Income Stat_2

Balance Sheet and Income Statement Footnotes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Operating Lease, Right-of-Use Asset	$ 0		$ 0
Operating Lease, Liability, Current	0		0
Accrued Liabilities, Current	181,873		181,873		$ 311,610
Accrued Payroll Taxes, Current	2,297		2,297
General and Administrative Expense	12,944	$ 30,313	155,941	$ 37,509
Employee Benefits and Share-Based Compensation			2,489
Professional Fees	4,000		9,200	900
Other Income	10,200
Interest Expense	5,646	$ 4,397
General and Administrative Expense [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
General and Administrative Expense			12,944	$ 30,313
Nickolas S. Tabraue [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Accrued Liabilities, Current	181,873		181,873
Accrued Payroll Taxes, Current	$ 126,410		$ 126,410

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)				6 Months Ended
	Oct. 31, 2022	Oct. 25, 2022	Oct. 24, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Proceeds from Notes Payable
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Notes Payable	$ 625,624
Subsequent Event [Member] | Saumat [Member] | Settlement Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			62,562,440
Subsequent Event [Member] | Saumat [Member] | Settlement Agreement [Member] | Preferred Stock [Member]
Subsequent Event [Line Items]
Shares, Issued			1,000,000
Subsequent Event [Member] | Dr Issa El Cheikh [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		16,300,000
Stock Issued During Period, Value, Restricted Stock Award, Forfeitures		$ 155,791
Subsequent Event [Member] | Mr Portala [Member] | Settlement And Release Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		2,750,000
Convertible Debt		$ 27,500
Subsequent Event [Member] | Nickolas S Tabraue And Mario G Tabraue [Member] | Preferred Stock [Member]
Subsequent Event [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited			1,000,000